Information Provided By: 
Fly News Breaks for August 6, 2019
PODD
Aug 6, 2019 | 07:37 EDT
Guggenheim analyst Chris Pasquale raised his price target on Insulet shares to $145 from $100 after the company's Q2 results topped consensus with upside that came from each of the company's three business segments. The company is seeing both accelerating new patient adds and positive pricing, which gives him confidence that Insulet can sustain top line growth above 20% over the next 2-3 years, said Pasquale, who keeps a Buy rating on the stock.
News For PODD From the Last 2 Days
There are no results for your query PODD
